Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, posted on X:
“TBCRC 048: good activity for olaparib in somatic BRCA1/2 altered advanced breast cancer patients.
- n=30
- ORR 37%, CBR 53%, mPFS7.2months, DOR-12.4m.”
